文献速递神经肿瘤

辅助化疗在H3K27变异型弥漫性中线胶质瘤患者中的作用:一项多中心回顾性研究

The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
PubMed 文献 · J Neurooncol · 2024-03-08

这项意大利多中心回顾性研究纳入49例成人H3K27变异型弥漫性中线胶质瘤患者,评估全身治疗的作用。辅助替莫唑胺与更长总生存相关(21.2 vs 9.0个月,HR 0.14),多因素分析确认其作用(HR 0.1);放疗和/或化疗后进展者接受二线全身治疗亦与生存获益相关(8.0 vs 3.2个月,HR 0.2)。

要点

  • 辅助替莫唑胺与更长总生存相关(21.2 vs 9.0个月,HR 0.14,p < 0.001)。
  • 多因素分析确认辅助化疗作用(HR 0.1,95%CI 0.03-0.34,p = 0.003)。
  • 进展后二线全身治疗与生存获益相关(8.0 vs 3.2个月,HR 0.2,p = 0.004)。

核心结论

  • 在该系列中,放疗后辅助治疗可能有助于改善H3K27变异型弥漫性中线胶质瘤患者的总生存。
  • 当可行时,治疗进展后可提出另一种全身治疗。

研究设计与样本

  • 意大利多中心回顾性研究,纳入6家机构的49例成人H3K27变异型弥漫性中线胶质瘤患者。
  • 中位年龄37.3岁(范围20.1-68.3)。
  • 多数患者以活检为主要手术方式(n = 30,61.2%),术后接受放疗(n = 39,79.6%)。
  • 25例(51.0%)接受同步化疗,26例(53.1%)接受辅助替莫唑胺。

主要发现

  • 单因素分析中,同步化疗未带来总生存改善,而辅助替莫唑胺与更长总生存相关(21.2 vs 9.0个月,HR 0.14,0.05-0.41,p < 0.001)。
  • 多因素分析确认辅助化疗的作用(HR 0.1,95%CI 0.03-0.34,p = 0.003)。
  • 在放疗和/或化疗后进展的患者中,接受二线全身治疗对生存有显著有利影响(8.0 vs 3.2个月,HR 0.2,95%CI 0.1-0.65,p = 0.004)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adult Diffuse midline glioma (DMG) is a very rare disease. DMGs are currently treated with radiotherapy and chemotherapy even if only a few retrospective studies assessed the impact on overall survival (OS) of these approaches. METHODS: We carried out an Italian multicentric retrospective study of adult patients with H3K27-altered DMG to assess the effective role of systemic therapy in the treatment landscape of this rare tumor type. RESULTS: We evaluated 49 patients from 6 Institutions. The median age was 37.3 years (range 20.1-68.3). Most patients received biopsy as primary approach (n = 30, 61.2%) and radiation therapy after surgery (n = 39, 79.6%). 25 (51.0%) of patients received concurrent chemotherapy and 26 (53.1%) patients received adjuvant temozolomide. In univariate analysis, concurrent chemotherapy did not result in OS improvement while adjuvant temozolomide was associated with longer OS (21.2 vs. 9.0 months, HR 0.14, 0.05-0.41, p < 0.001). Multivariate analysis confirmed the role of adjuvant chemotherapy (HR 0.1, 95%CI: 0.03-0.34, p = 0.003). In patients who progressed after radiation and/or chemotherapy the administration of a second-line systemic treatment had a significantly favorable impact on survival (8.0 vs. 3.2 months, HR 0.2, 95%CI 0.1-0.65, p = 0.004). CONCLUSION: In our series, adjuvant treatment after radiotherapy can be useful in improving OS of patients with H3K27-altered DMG. When feasible another systemic treatment after treatment progression could be proposed.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Di Nunno V, Lombardi G, Simonelli M, et al. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study. J Neurooncol. 2024. PMID: 38457090. doi:10.1007/s11060-024-04589-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。